IL161942A0 - (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol - Google Patents
(+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinolInfo
- Publication number
- IL161942A0 IL161942A0 IL16194299A IL16194299A IL161942A0 IL 161942 A0 IL161942 A0 IL 161942A0 IL 16194299 A IL16194299 A IL 16194299A IL 16194299 A IL16194299 A IL 16194299A IL 161942 A0 IL161942 A0 IL 161942A0
- Authority
- IL
- Israel
- Prior art keywords
- morpholinol
- chlorophenyl
- trimethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801230.5A GB9801230D0 (en) | 1998-01-21 | 1998-01-21 | Pharmaceutically active morpholinol |
| US7218098P | 1998-01-22 | 1998-01-22 | |
| PCT/US1999/001134 WO1999037305A1 (en) | 1998-01-21 | 1999-01-20 | Pharmaceutically active morpholinol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161942A0 true IL161942A0 (en) | 2005-11-20 |
Family
ID=26312986
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16194299A IL161942A0 (en) | 1998-01-21 | 1999-01-20 | (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol |
| IL13734699A IL137346A0 (en) | 1998-01-21 | 1999-01-20 | Pharmaceutically active morpholinol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13734699A IL137346A0 (en) | 1998-01-21 | 1999-01-20 | Pharmaceutically active morpholinol |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6274579B1 (no) |
| EP (2) | EP1047428B1 (no) |
| JP (1) | JP2002501025A (no) |
| KR (1) | KR100568063B1 (no) |
| CN (2) | CN1203858C (no) |
| AP (1) | AP1229A (no) |
| AT (1) | ATE365042T1 (no) |
| AU (1) | AU755536B2 (no) |
| BR (1) | BR9907203A (no) |
| CA (1) | CA2318268A1 (no) |
| CY (1) | CY1106828T1 (no) |
| DE (1) | DE69936335T2 (no) |
| DK (1) | DK1047428T3 (no) |
| EA (1) | EA002410B1 (no) |
| EE (1) | EE04452B1 (no) |
| ES (1) | ES2288012T3 (no) |
| HR (2) | HRP20000494B1 (no) |
| HU (1) | HUP0100900A3 (no) |
| ID (1) | ID26334A (no) |
| IL (2) | IL161942A0 (no) |
| IS (1) | IS2494B (no) |
| NO (2) | NO326878B1 (no) |
| NZ (3) | NZ529316A (no) |
| PL (1) | PL193622B1 (no) |
| PT (1) | PT1047428E (no) |
| SG (1) | SG115489A1 (no) |
| SK (1) | SK10912000A3 (no) |
| TR (1) | TR200002126T2 (no) |
| WO (1) | WO1999037305A1 (no) |
| YU (1) | YU67102A (no) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098206B2 (en) | 1998-01-21 | 2006-08-29 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6998400B2 (en) | 1998-01-22 | 2006-02-14 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| JP2002501891A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（＋）−ビュープロピオンの医薬用途 |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US6855820B2 (en) | 1999-01-20 | 2005-02-15 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6734213B2 (en) | 1999-01-20 | 2004-05-11 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| AU7750100A (en) * | 1999-10-13 | 2001-04-23 | Glaxo Group Limited | Method for the treatment of obesity |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| US7145649B2 (en) * | 2000-12-21 | 2006-12-05 | Brasscorp Limited | Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing |
| US6979104B2 (en) | 2001-12-31 | 2005-12-27 | R.J. Doran & Co. LTD | LED inspection lamp |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| KR101072885B1 (ko) * | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
| ATE413882T1 (de) * | 2002-08-23 | 2008-11-15 | Lilly Co Eli | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren |
| GB0219687D0 (en) * | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| JP2007509856A (ja) * | 2003-10-27 | 2007-04-19 | スミスクライン ビーチャム コーポレーション | （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するための酵素触媒動的速度論分割方法 |
| GB0325055D0 (en) * | 2003-10-27 | 2003-12-03 | Smithkline Beecham Corp | New process |
| GB0326148D0 (en) * | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| GB0327619D0 (en) * | 2003-11-27 | 2003-12-31 | Smithkline Beecham Corp | New use |
| CA2553207A1 (en) | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| CA2565154A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
| FI117283B (fi) | 2005-02-04 | 2006-08-31 | Kone Corp | Hissijärjestelmä |
| JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
| EP1968603A4 (en) * | 2006-01-03 | 2013-01-16 | Algebra Inc | THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
| CN101588795A (zh) | 2006-11-09 | 2009-11-25 | 奥雷西根治疗公司 | 包含中间快速溶解层的分层药物制剂 |
| US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| AU2010236404B2 (en) | 2009-04-15 | 2016-11-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
| EP3659604A1 (en) | 2010-01-11 | 2020-06-03 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| WO2011146821A2 (en) | 2010-05-21 | 2011-11-24 | Research Triangle Institute | 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| AU2011255276B2 (en) | 2010-05-21 | 2016-09-22 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| US9510405B2 (en) | 2011-06-30 | 2016-11-29 | Schneider Electric Industries Sas | Dual power SMPS for a modular lighting system |
| CN102670617B (zh) * | 2012-04-13 | 2013-03-20 | 湖南大学 | 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用 |
| HUE049859T2 (hu) | 2012-06-06 | 2020-10-28 | Nalpropion Pharmaceuticals Llc | Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| RU2763728C1 (ru) * | 2021-06-17 | 2021-12-30 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US170430A (en) * | 1875-11-30 | Improvement in furnaces for heating steel in tempering | ||
| GB8417170D0 (en) * | 1984-07-05 | 1984-08-08 | Wellcome Found | Heterocyclic pharmaceutical compounds |
| GB9108629D0 (en) | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
-
1999
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en active IP Right Grant
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active IP Right Cessation
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
-
2000
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-21 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
-
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
-
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
-
2005
- 2005-12-29 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
-
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
-
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161942A0 (en) | (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol | |
| DE69941083D1 (en) | 12,13-cyclopropan-epothilonderivate | |
| GB9929000D0 (en) | Reamer shoe | |
| HUP0102483A3 (en) | Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol | |
| GB9814325D0 (en) | Headwear | |
| ZA200005369B (en) | Calcilytic compounds. | |
| ZA200005510B (en) | Pharmaceutical composition. | |
| GB9817235D0 (en) | Compound,composition and use | |
| HK1038166A1 (en) | Toothbrush. | |
| GB9817236D0 (en) | Compound,composition and use | |
| PL352285A1 (en) | Phenoxy fluoropyrimidines | |
| GB9903447D0 (en) | Compound, composition and use | |
| AU2656799A (en) | Metal-thiols as imminomodulating agents | |
| ZA992899B (en) | Novel compound. | |
| GB0100361D0 (en) | Compound, composition and use | |
| HK1044117A1 (en) | Pharmaceutical composition. | |
| ZA200006118B (en) | Novel composition. | |
| AU2964899A (en) | 2,4-dioxo-5-arylidenimino-1,3-pyrimidines | |
| ZA993225B (en) | Cooling reservoir. | |
| ZA200000192B (en) | Novel composition. | |
| AU3196000A (en) | 3,3'-diketotrehalose | |
| ZA99985B (en) | New compound. | |
| IL158978A (en) | Salts and solvates of the compound (+)-(2s,3s)-2-(3-chlorophenyl) -3,5,5- trimethyl-2-morpholinol | |
| ZA991761B (en) | New agent. | |
| ZA99925B (en) | Composition. |